MedWatch

Genmab CEO on possible settlement in dispute with Janssen: "I have no comment"

Genmab CEO Jan van de Winkel is not keen on commenting on the possibility of a settlement in the dispute between Genmab and partner Janssen concerning the distribution of earnings from the cancer drug Darzalex, according to Danish newspaper Børsen.

Genmab CEO Jan van de Winkel | Photo: Stine Bidstrup/ERH

Danish pharmaceutical company Genmab intends to defend the stances of the firm in its current dispute with its former partner Janssen Pharmaceuticals on the distribution of the earnings from the cancer drug Darzalex, according to Danish newspaper Børsen.

Genmab CEO Jan van de Winkel tells the newspaper that the arbitration case is actively ongoing but that the timing of the case is uncertain. On the matter of whether the dispute might end with a settlement, the CEO tells Børsen:

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs